drugset / Trial / NCT07317544

Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

NCT07317544 ↗

Phase 1/2 Recruiting 227 enrolled Absci Pty Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if ABS-201 (a new medication) is safe and tolerable when used to improve hair growth in men and women. The trial will start with healthy volunteers and if safe, will treat participants with certain types of hair loss. The main questions it aims to answer are: What medical problems, if any, do participants experience when taking a single dose or many doses of ABS-201? How does the medication, ABS-201, compare to placebo (a look alike substance that does not contain any medication). Participants who qualify for the trial will receive either ABS-201 or a placebo, and visit the study clinic for scheduled checkups and tests for approximately 1 year.

Timeline

Start
2025-12-03
Primary completion
2028-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ABS-201 Monoclonal antibody 150 mg Intravenous
Subject ABS-201 Monoclonal antibody 300 mg Intravenous
Subject ABS-201 Monoclonal antibody 450 mg Intravenous
Subject ABS-201 Monoclonal antibody 600 mg Intravenous
Subject ABS-201 Monoclonal antibody 900 mg Intravenous
Subject ABS-201 Monoclonal antibody 1200 mg Intravenous
Subject ABS-201 Monoclonal antibody 1800 mg Intravenous

Indications